Published: 2021-02-23

The role of NT-proBNP in the diagnosis of diastolic heart failure and its correlation with echocardiography

Archana Toppo, Sanjay Varma, Aneesh Karwa, Rajeev Lochan Khare, Yogendra Malhotra


Background: The primary aim of the current investigation was to evaluate the role of NT-proBNP in the diagnosis of diastolic heart failure and its correlation with echocardiography.

Methods: Hospital based observational and analytical study undertaken on a total of 65 patients of diastolic heart failure fulfilling clinical inclusion criteria. The enrolled patients had a mean age of 54.5 years with a female preponderance (33 females vs. 32 males). Patients underwent clinical evaluation and echocardiography examination. NT-proBNP estimation was done using autoanalyzer working on principle of electrochemiluminisense. Patients were divided into various grades of diastolic dysfunction on the basis of echocardiography. Statistical analysis was done to find the significance of levels of NT-proBNP and its correlation with the grading of diastolic heart failure.

Results: There was a statistically significant higher level of serum NT-proBNP in patients with diastolic heart failure and the increasing levels were directly proportional to severity of diastolic dysfunction. The mean level of NT-proBNP increased from 361.08 pg/ml to 3570 pg/ml in increasing severity of diastolic dysfunction.

Conclusions: Results suggested positive correlation of rising NT-proBNP levels with increasing severity of diastolic dysfunction.



NT-proBNP, Diastolic heart failure, Echocardiography

Full Text:



Ramakrishnan S. Heart failure-definition and diagnosis. Heart Fail. 2005;13-20.

Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: Diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387-93.

Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. 2009;22:165-93.

Mueller C, Breidthardt T, Laule-Kilian K, Christ M, Perruchoud AP. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly. 2007;137(1-2):4-12.

Armstrong WiF, Ryan T, Feigenbaum H. Feignebaum’s Echocardiography. 6th ed. USA: Lippincott Williams & Wilkins; 2010:816.

Downie PF, Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL, et al. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro : implications for assessment of left ventricular dysfunction. Clin Sci. 1999;258:255-8.

Stimson NF. National Institutes of Health public access policy assistance: one library's approach. J Med Libr Assoc. 2009;97(4):238-40.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27):2129-200.

Hill SA, Booth RA, Santaguida PL, Don-Wauchope A, Brown JA, Oremus M, Ali U, Bustamam A, Sohel N, McKelvie R, Balion C, Raina P. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev. 2014;19(4):421-38.

Lee CY, Burnett JC. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12(2): 131-42.

Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail. 2004;6(3):257-60.

Goetze JP. Biochemistry of pro-B-type natriuretic peptide-derived peptides: The endocrine heart revisited. Clin Chem. 2004;50(9):1503-10.

Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92(6):843-9.

Gunning M, Ballermann BJ, Silva P, Brenner BM, Zeidel ML. Brain natriuretic peptide: interaction with renal ANP system. Am J Physiol. 1990;258(3):F467-72.

Grewal J, McKelvie R, Lonn E, Tait P, Carlsson J, Gianni M, et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail. 2008;10(3):252-9.

Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JE. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. BMJ. 2002;324(7352):1498.

Panjiyar RK, Rs T, Laudari S, Gupta M, Dhungel S, Dubey L, et al. A clinical study of heart failure with preserved ejection fraction in patients at college of medical sciences , teaching hospital : a tertiary centre from. Int J Sci Res Pub. 2017;7(12):58-62.

McMurray JJ, Carson PE, Komajda M, McKelvie R, Zile MR, Ptaszynska A, Staiger C, Donovan JM, Massie BM. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail. 2008;10(2):149-56.

Tschöpe C, Kašner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: Correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26(21):2277-84.